The YODA Project
Research Proposal Due Diligence Assessment

Part 1: General Information	
YODA Project (Protocol) ID:	2020-4517
Date:	7 December 2020
Product Name:	Risperidone/ Paliperidone
Therapeutic Area:	Neuroscience
Product Class:	Atypical antipsychotics
Condition(s) Studied:	Schizophrenia
Protocol Number(s) and Title(s):	**NCT01009047** R076477PSZ3003 **NCT00086320** R076477-SCH-301 **NCT00645099** R076477SCH3020 **NCT01662310** R076477-SCH-3041 **NCT00111189** R092670PSY3001 **NCT00210717** R092670PSY3002 **NCT01529515** R092670PSY3012 **NCT01193153** R092670SCA3004 **NCT00236457** RIS-INT-62 **NCT00216476** RISSCH3001 **NCT00299702** RISSCH4060 **NCT00992407** RISSCH4178 **NCT00236379** RIS-USA-275

Part 2: Data Availability	
Question:	**Response:**
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments: N/A	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments: N/A	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments: N/A	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments: N/A	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments: N/A	

Part 3: Data Availability Summary	
Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.	Yes

The YODA Project
Research Proposal Due Diligence Assessment

Part 4: Proposal Review	
Question:	**Response:**
Summary-level CSR data is appropriate for the proposed analysis.	Yes
Participant-level data is appropriate for the proposed analysis.	No
A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments:	